Guggenheim raised the firm’s price target on Dianthus (DNTH) to $200 from $100 and keeps a Buy rating on the shares. Following adjustments to the firm’s model, it revised its claseprubart global peak sales estimate up to $2.8B in CIDP patients and now estimates about $2B in gMG global sales.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus Therapeutics: Best-in-Class Complement Inhibitor Potential and Multiple 2026 Catalysts Support Buy Rating
- Dianthus Therapeutics: Multi-Indication Potential for Claseprubart Underpins Buy Rating Ahead of Key Phase II Readouts
- Dianthus participates in a conference call with William Blair
- Pipeline-in-a-Product Momentum: De-Risked Autoimmune Neurology Catalyst Path Justifies Buy Rating on Claseprubart Franchise
- Dianthus price target raised to $125 from $62 at Oppenheimer